The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies

In plain words

This is a short review article about using artificial intelligence to find and design new medicines. It covers where AI already helps, such as predicting whether a candidate drug will work or be harmful, designing new molecules and speeding up trials, and where it falls short, mainly because good data is scarce and the results can be biased or hard to explain.

The article is also an experiment. The authors asked the ChatGPT chatbot to draft it, then checked and largely rewrote the text. So it is a useful map of the topic from December 2022, but it is not a new method and it reports no experiments of its own. Its references need checking before anyone relies on them.

TL;DR

A narrative review, not a method paper. It surveys AI for drug efficacy and toxicity prediction, drug design, case studies, collaboration, challenges and ethics, and suggests data augmentation, explainable AI and combining AI with lab work as ways forward §1–§9. It has no experiments, so there is nothing to reproduce. Its citations are unreliable in places (see Pitfalls).

Problem

Drug discovery is slow and costly. Current medicinal chemistry relies on trial-and-error and large-scale testing, which is slow, expensive and often gives low accuracy, and the test compounds may not predict behaviour in the body §2, p. 3. The review argues that AI methods, trained on large amounts of data, could improve on these limits §2, p. 3.

Method

This paper proposes no drug-discovery method and has no equations. It is a narrative review. The only procedure it describes is how the text was drafted, which is written out below as pseudocode p. 2. The review's sections follow.

# Drafting procedure the authors describe  [p. 2]
# Input:  human prompts for each section, plus the section plan
# Output: manuscript, revised by human authors

def draft_review(prompts, sections):
    # Generate a preliminary text for each section with ChatGPT  [p. 2]
    preliminary = {}
    for section in sections:
        preliminary[section] = chatgpt(prompts[section])
    # Correct and enrich the text, and remove repetitions  [p. 2]
    # Replace the references the chatbot suggested  [p. 2]
    # Repeat the revisions until the authors are satisfied  [p. 2]
    manuscript = human_revise(preliminary)
    return manuscript

The review's sections, in order, and the claims each one makes:

• Introduction §1, p. 2: AI (machine learning and natural language processing) could speed up and improve drug discovery. Deep learning has been used to predict drug efficacy and toxicity.
• Limitations of current methods §2, p. 3: trial-and-error and high-throughput screening are slow and costly. AI methods could predict efficacy and toxicity more accurately and find new targets.
• Efficacy and toxicity prediction, drug-drug interactions §3, pp. 3–4: ML can find patterns in compound data and predict activity and toxicity. It can also predict drug-drug interactions and support personalised medicine.
• Design of new compounds and cost savings §4, p. 4: AI can propose molecules with target properties, such as solubility and activity. AlphaFold predicts protein 3D structure from sequence. ML combined with molecular dynamics is proposed for de novo design.
• Case studies §5, pp. 4–5: cancer compound discovery, MEK inhibitors, BACE1 inhibitors for Alzheimer's, antibiotic discovery from a pool of more than 100 million molecules, and COVID-19 drug discovery and repurposing.
• Collaboration between AI researchers and pharma §6, p. 5: joint work can improve trial accuracy and efficiency, and help target patient groups. The one example given is a Merck and Numerate collaboration.
• Challenges §7, pp. 5–6: data availability and quality, bias and fairness. Proposed remedies are data augmentation with synthetic data §7 and explainable AI for transparent predictions §7. AI cannot replace experts and its results must be validated §7.
• Ethics §8, p. 6: concerns are AI-made decisions about drugs and trials, bias leading to unequal access to treatment, job loss from automation, and privacy and misuse of sensitive medical data.
• Conclusion §9, p. 6: AI can improve efficiency and accuracy, but its success depends on high-quality data, ethics and knowing its limits.
• Expert opinion on ChatGPT §10, pp. 6–7: the authors' own assessment of the drafting experiment, with recommendations for AI-written science (see Pitfalls).

Hyperparameters

Not applicable. The paper reports no models, training runs or settings §1.

Results

No experiments. The only numbers are the authors' own measurements of the drafting process, taken from the Methods box. They are author-reported and not independently checked. Setup: a preliminary text drafted by ChatGPT, based on GPT-3.5 and released 30 November 2022, compared with the final manuscript p. 2.

Paper vs code

No official code. The paper has no method to implement. The only URLs in the text are references (Copyleaks, OpenAI, a press site). I searched GitHub for the author surname with the WebFetch tool (api.github.com/search/repositories); none of the 23 hits is owned by an author, so there is no official repository.

Pitfalls

• Not a method or evaluation. Nothing here can be implemented or benchmarked. Use it for context and for the list of open problems, not for effect sizes. Its claims about AI benefits are narrative and mostly not quantified.
• Drafted by a chatbot. The preliminary text was generated by ChatGPT, and the authors then "practically rewrote" the manuscript p. 1. The authors state that "nearly all the references" in the chatbot's draft were clearly incorrect §10, p. 7. Treat every citation as unverified until checked against its source.
• Citations that do not match the claim. The titles and types of several references suggest they do not support the sentences they are attached to. For example:
  • ref. 38 is a press release about a company's headquarters move. It is cited for the Merck–Numerate collaboration §6, p. 5.
  • ref. 21 is a general review on AI for drug discovery. It is cited for a specific cancer case study §5, p. 4.
  • ref. 11 is about many-body potentials and molecular properties in chemical space. It is cited for a deep-learning model of drug activity §3, p. 3.
  • ref. 37 has garbled text, and refs. 1, 2 and 39 are a bare "OpenAI." entry, a website and a web page.
• Non-peer-reviewed sources. Several references are news items, press releases or websites (refs. 1, 2, 25, 37–39), so claims resting on them are weak.
• Dated. The authors state that the ChatGPT model they used was trained on data up to 2021 §10, p. 7. The review reflects the field as of its December 2022 publication date. Check any claim about current tools or results.
• Similarity figures are unclear. How the 4.3%, 13.3% and 16.3% similarity figures were computed is not stated p. 2. The three categories are not stated to add up to a total.
• Missing supporting material. The Supporting Information, which holds the original ChatGPT output and the prompts p. 2, is not in the fetched source. It was not used.
• Illustration. The image on page 2 is AI-generated (DALL-E) and is not reproduced here. No images are used on this page.

Lineage

• Builds on: none. It is a review that cites earlier reviews on AI in drug development (e.g. Paul et al., 2021 [ref. 3]); those have no card here.
• Compared against: none. The paper reports no comparison.
• Superseded by: not known from content in this wiki.